XNAS
LFMDP
Market cap222mUSD
Jul 10, Last price
23.21USD
1D
0.47%
1Q
-2.18%
IPO
-3.80%
Name
LifeMD Inc
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
LifeMD, Inc. functions as a direct-to-patient telehealth enterprise, linking individuals with healthcare professionals throughout the United States for a diverse array of medical concerns. These services encompass everything from personalized concierge care to specialized fields such as men's sexual health and dermatology. The company operates a portfolio of distinct telehealth brands. ShapiroMD is dedicated to comprehensive hair loss solutions, offering virtual consultations, prescription medications, unique over-the-counter products, an FDA-approved medical device, and specialized compounded topical treatments for both male and female hair loss. RexMD provides virtual medical treatment from licensed providers for various men's health requirements. LifeMD Primary Care is a subscription-based, mobile-first platform delivering personalized virtual primary, urgent, and chronic care, integrating online consultations, prescription services, diagnostics, and imaging. Cleared focuses on customized treatments for allergy, asthma, and immunological conditions. Nava MD serves as a female-oriented tele-dermatology and skincare brand, facilitating virtual medical consultations with dermatologists and other experts. Beyond its healthcare focus, LifeMD also manages PDFSimpli, an online software-as-a-service (SaaS) platform that empowers users to create, edit, convert, sign, and share PDF documents. The company distributes its products and services directly to consumers, through e-commerce channels, and via third-party partner networks. Initially established in 1994 as Conversion Labs, Inc., the company officially rebranded to LifeMD, Inc. in February 2021. Its corporate headquarters are located in New York, New York.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||